Tumor necrosis factor: Biology and therapeutic inhibitors

Gastroenterology

Volumn 119, Issue 4, 2000, Pages 1148-1157

  Papadakis, K A ^a   Targan, S R ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 2; COLONY STIMULATING FACTOR 1; CYTOKINE; DNA; ETANERCEPT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LYMPHOTOXIN; MESSENGER RNA; METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PENTOXIFYLLINE; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; THALIDOMIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; AUTOIMMUNE DISEASE; CELL PROLIFERATION; CROHN DISEASE; CYTOKINE PRODUCTION; GENETIC ORGANIZATION; HUMAN; MACROPHAGE; MOLECULAR BIOLOGY; MONOCYTE; MUCOSA INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR NECROSIS;

EID: 0033778364     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2000.18160     Document Type: Article

References (78)

1. Tumor necrosis factor (TNF)
2. Seminars in Medicine of the Beth Israel Hospital, Boston: The tumor necrosis factor ligand and receptor families
3. The biology of cachectin/TNF - A primary mediator of the host response
4. Tumor necrosis factor: Pleiotrophic cytokine and therapeutic target
5. Differential activities of secreted lymphotoxin-α3 and membrane lymphotoxin-α1β2 in lymphotoxin-induced inflammation: Critical role of TNF receptor 1 signaling
6. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kB activation prevents cell death
7. Feedback inhibition of macrophage tumor necrosis factor-α production by tristetraprolin
8. Essential role of tumor necrosis factor α in alcohol-induced liver injury in mice
9. The pathophysiology of tumor necrosis factors
10. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages
11. + T cells
12. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation
13. Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia
14. Mast cells are an important cellular source of tumor necrosis factor alpha in human intestinal tissue
15. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion
16. Tumor necrosis factor locus. Genetic organization and biological implications
17. C/EBPβ regulation of tumor necrosis factor α gene
18. ETS transcription factors regulate an enhancer activity in the third intron of TNF-alpha
19. Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN
20. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies
21. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-α) translation: Glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK
22. Identification of TIAR as a protein binding to the translational regulatory AU-rich element of tumor necrosis factor α mRNA
23. Different mitogen-activated protein kinase signaling pathways cooperate to regulate tumor necrosis factor α gene expression in T lymphocytes
24. Cutting edge: A dominant negative form of TNF-α converting enzyme inhibits proTNF and TNFRII secretion
25. Tumor necrosis factor and Crohn's disease
26. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor
27. Signal transduction by tumor necrosis factor: The Parker B. Francis lectureship
28. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes
29. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains
30. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase
31. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection
32. Decreased sensitivity to tumor necrosis factor but normal T-cell development in TNF receptor-2-deficient mice
33. Peyer's patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor
34. Lymphotoxin α/β and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen
35. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin
36. Role of cytokines in the pathogenesis of inflammatory bowel disease
37. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-α for Crohn's disease. Crohn's disease cA2 Study Group
38. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice
39. Contribution of TNF receptor (TNFR) types and T lymphocyte populations to the pathogenesis of experimental Crohn's disease (CD) in TNF(ΔARE) mutant mice
40. Current theories on the cause of inflammatory bowel disease
41. +CD45RB(hi) T cells
42. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils
43. Small bowel enteropathy: Role of intraepithelial lymphocytes and of cytokines (IL-12, IFN-γ, TNF) in the induction of epithelial cell death and renewal
44. Differential and regulated expression of C-X-C, C-C, and C-chemokines by human colon epithelial cells
45. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-α ligation of Fas antigen
46. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis
47. Cytokine profiles of cultured microvascular endothelial cells from the human intestine
48. A role of TNF-α and mucosal Th-1 cytokines in the pathogenesis of Crohn's disease
49. A soluble factor produced by lamina propria mononuclear cells is required for TNF-α enhancement of IFN-γ production by T cells
50. TNF-alpha induction of CD44-mediated leukocyte adhesion by sulfation
51. Tumour necrosis factor-alpha enhances intraepithelial lymphocyte proliferation and migration
52. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production
53. Endotoxin-mediated dendritic cell release from the intestine: Characterization of released dendritic cells and TNF dependence
54. Enhanced epidermal Langerhans cell migration in IL-10 knockout mice
55. Dendritic cells
56. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites
57. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNF α
58. Tumor necrosis factor-α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's enterocolitis
59. Infliximab for the treatment of fistulas in patients with Crohn's disease
60. Cytokine-based therapies in inflammatory bowel disease
61. Taming TNF: Strategies to restrain this proinflammatory cytokine
62. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease
63. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha
64. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
65. Inhibition of IL-12 production by thalidomide
66. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
67. Role of NF-κB in immune and inflammatory responses in the gut
68. Mucosa-specific targets for regulation of IFN-γ expression: Lamina propria T cells use different cis-elements than peripheral blood T cells to regulate transactivation of IFN-γ expression
69. Mechanism of action of bicyclic imidazoles defines a translational regulatory pathway for tumor necrosis factor alpha
70. Therapeutic potential and strategies for inhibiting tumor necrosis factor-α
71. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation
72. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor-κB activation in mouse colonocytes
73. Salicylates inhibit IκB-α phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration
74. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF-α processing in RA synovial membrane cell cultures
75. The effect of a metalloproteinase inhibitor (GI5402) on tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha receptors during human endotoxemia
76. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
77. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions
78. Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease